ProMIS Neurosciences Inc PMN

What's bringing us down ?

[Thenorth1990]

- bad news that came for aducanumab after approval ? - no funding yet ? - or shelf prospectus What do u guys think ?

[M101]

Hard habit to break while management remains an issue. If you're trading on no news before labour day don't you still sell here to buy then?   I still think we're on a staircase pattern (ascending) that resumes before X-mas, so that would be a significant divergence from previous years.

[Mole101]

I'm surprisingly  agreen with you on this one M... I don't think there is much happening through the summer to move sp upward. I'll seat on what I have and may add as the ocasiones arise .. quote=M101]Hard habit to break while management remains an issue. If you're trading on no news before labour day don't you still sell here to buy then?   I still think we

[DavidKingCanada]

Lets rephrase that, what has PMN done to Increase the SP? Nothing as of yet. 2021 was a great year for PR's but other than that not too much movement.  Keep in mind, Biogen has Aducanumab and PMN has PMN310. Any negative news for Aducanumab may be helping us in the long run.  You will notice most people complain about Management but it is very impressive that they have

[G1945V]

DKC, you say... "Keep in mind, Biogen has Aducanumab and PMN has PMN310. Any negative news for Aducanumab may be helping us in the long run. " I'm not sure I agree with that. Aducanumab keeps the Amyloid Beta hypothesis alive and well, and that helps PMN310. We need medical practitioners to promote Aducanumab and stop the negativity despite limited and controversial efficacy

[DavidKingCanada]

Definitely Biogen is the "First in Class" but like RC has stated, any negative news for Aducanumab might benefit PMN. I would love to Invest in Biogen but at the Current SP its too much for us. Not sure about others but I still believe PMN is undervalued. Good luck to you and wishing everyone the best! 

[M101]

Well that's the Goldstein hypothesis anyway, and how has it worked so far? Please consider the alternative hypothesis, where our consultants had positioned PMN as cheerleading Aducanumab's failure, qualified approval notwithstanding, same facts but reverse spin, e.g., It will fail because it is not selective...It did fail because it is not selective.  It's not really much of a

[DavidKingCanada]

Agreed! Thanks M101

[G1945V]

M101: Not sure I understand your point of view, but the Amyloid hypothesis is still alive and aducanumab has thus far maintained that view. Not sure why you are saying that the hypothesis somehow belongs to Goldstein. The hypothesis continues and PMN310 has a good opportunity to improve it. PMN310 selectivity is yet to be proven. Only clinicals can do that. Perhaps we're saying the same thing

[M101]

Or, Aducanumab is just one of many failures in the field of ACH, which neither proves nor disproves it.  Taken collectively though there have been so many failures that there is still no theory arising from the hypothesis.  Goldstein's hypothesis is that his incompetence as our CEO is excusable because Aducanumab was in limbo, the implication being that his many quality-investor

[DavidKingCanada]

M101; Not sure if you have me on Ignore, but would really like your input on the possibility of Mr. Warma becoming the new CEO. Where do you think PMN will head towards come 2022? Will we still have board that in incompetent or a board that can actually get stuff done?